Report of Foreign Issuer (6-k)
07 December 2018 - 8:45AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: December 2018
Commission file number: 001-36578
BIOBLAST
PHARMA LTD.
(Translation of registrant’s name
into English)
PO Box 318, Tel-Aviv, Israel 6100201
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
x
Form
40-F
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):
¨
On November 21, 2018,
the Registrant provided notice of an Annual and Extraordinary General Meeting of Shareholders to be held on December 26, 2018 (the
“
Meeting
”), for the purpose of approving certain resolutions required to consummate a merger and other transactions
as described in such notice, as well as other resolutions.
Attached
hereto and incorporated by reference herein is the Registrant
’
s Amendment to Notice
of Meeting which reschedules the Meeting from December 26, 2018 to December 27, 2018. The agenda for the Meeting as well as the
record date for the Meeting will not change. In addition, attached hereto and incorporated by reference herein are the Registrant’s
Proxy Statement and Proxy Card for the Meeting.
Only shareholders of record
who hold Ordinary Shares, nominal value NIS 0.05, of the Registrant at the close of trading on the Nasdaq Capital Market on November
26, 2018, will be entitled to notice of and to vote at the Meeting and any postponements or adjournments thereof.
The
Notice of Meeting, Proxy Statement and Proxy Card attached to this Form 6-K of the Registrant are incorporated by reference into
the registration statements on Form S-8 (File No. 333-203114 and File No. 333-210459) of the Registrant, filed with the Securities
and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by
documents or reports subsequently filed or furnished.
Exhibit No.
99.1
|
Amended Notice
of Meeting for the Annual and Extraordinary General Meeting of Shareholders to be held on December 27, 2018.
|
99.2
|
Proxy Statement for the Annual and Extraordinary General Meeting of Shareholders to be held on December 27, 2018.
|
99.3
|
Proxy Card for the Annual and Extraordinary General Meeting of Shareholders to be held on December 27, 2018.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Bioblast Pharma Ltd.
|
|
(Registrant)
|
|
|
|
|
|
|
|
By:
|
/s/ Dr. Dalia Megiddo
|
|
Name:
|
Dr. Dalia Megiddo
Interim Chief Executive Officer
|
Date: December 6, 2018
Bioblast Pharma Ltd. (NASDAQ:ORPN)
Historical Stock Chart
From Apr 2024 to May 2024
Bioblast Pharma Ltd. (NASDAQ:ORPN)
Historical Stock Chart
From May 2023 to May 2024